Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Chromatin-modifying protein 4C (CHMP4C) affects breast cancer cell growth and doxorubicin resistance as a potential breast cancer therapeutic target

The Journal of Antibiotics volume 77, pages 93–101 (2024)Cite this article

Subjects

Abstract

Breast cancer (BCa) is one of the common malignancies among women. Doxorubicin (Dox), a type of anthracycline anti-tumor drug, is a first-line chemotherapy drug for BCa. It is badly needed to effectively reverse BCa resistance to Dox and improve the clinical symptoms of BCa. Chromatin Modification protein 4C (CHMP4C) is a subunit of the endosomal sorting complex and is expressed in the nucleus and cytoplasm. CHMP4C has been shown to be overexpressed in multiple types of cancers. However, its possible effects on the progression and drug resistance of BCa are still unclear. In this study, we found CHMP4C was highly expressed in BCa tissues and promoted cell proliferation. In addition, CHMP4C promoted resistance of BCa cells to Dox through targeting Snail. We further found that knockdown of CHMP4C inhibited tumor growth and enhanced sensitivity to Dox in vivo. We therefore thought CHMP4C could serve as a target for decreasing BCa drug resistance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kim YJ, Jang SK, Kim G, Hong SE, Park CS, Seong MK, et al. Nebivolol sensitizes BT-474 breast cancer cells to FGFR inhibitors. Anticancer Res. 2023;43:1973–80.

    Article  CAS  PubMed  Google Scholar 

  2. Yamanaka T, Oshima T, Murayama D, Okamoto S, Matsui AI, Yasukawa M, et al. Clinical significance of cancer stem cell markers in primary and metastatic tissues in patients with breast cancer. Anticancer Res. 2023;43:2145–54.

    Article  CAS  PubMed  Google Scholar 

  3. Das CK, Linder B, Bonn F, Rothweiler F, Dikic I, Michaelis M, et al. BAG3 overexpression and cytoprotective autophagy mediate apoptosis resistance in chemoresistant breast cancer cells. Neoplasia. 2018;20:263–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Liu H, Yan R, Xiao Z, Huang X, Yao J, Liu J, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling. Breast Cancer Res. 2023;25:43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wei X, Yang M. Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy. Front Pharmacol. 2023;14:1180794.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zaib S, Tahir S, Masood N, Hameed A, Azra Y. A meta-analysis and experimental data for multidrug resistance genes in breast cancer. Afr Health Sci. 2022;22:1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Li J. Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer. BMC Cancer. 2023;23:353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lin SL, Wang M, Cao QQ, Li Q. Chromatin modified protein 4C (CHMP4C) facilitates the malignant development of cervical cancer cells. FEBS Open Bio. 2020;10:1295–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Carlton JG, Caballe A, Agromayor M, Kloc M, Martin-Serrano J. ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C. Science. 2012;336:220–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Petsalaki E, Dandoulaki M, Zachos G. The ESCRT protein Chmp4c regulates mitotic spindle checkpoint signaling. J Cell Biol. 2018;217:861–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Petsalaki E, Zachos G. CHMP4C: a novel regulator of the mitotic spindle checkpoint. Mol Cell Oncol. 2018;5:e1445944.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chen Y, Liu Y, Wang M. Identification of a pyroptosis-related gene signature and effect of silencing the CHMP4C and CASP4 in pancreatic adenocarcinoma. Int J Gen Med. 2022;15:3199–213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Liu B, Guo S, Li GH, Liu Y, Liu XZ, Yue JB, et al. CHMP4C regulates lung squamous carcinogenesis and progression through cell cycle pathway. J Thorac Dis. 2021;13:4762–74.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Li K, Liu J, Tian M, Gao G, Qi X, Pan Y, et al. CHMP4C disruption sensitizes the human lung cancer cells to irradiation. Int J Mol Sci. 2015;17.

  15. Xu S, Li X, Li W, Ma N, Ma H, Cui J, et al. Sufentanil combined with parecoxib sodium inhibits proliferation and metastasis of HER2-positive breast cancer cells and regulates epithelial-mesenchymal transition. Clin Exp Metastasis. 2023;40:149–60.

    Article  CAS  PubMed  Google Scholar 

  16. Azadeh M, Salehzadeh A, Ghaedi K, Talesh Sasani S. NEAT1 can be a diagnostic biomarker in the breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: integrated RNA targetome interaction and experimental expression analysis. Genes Environ. 2022;44:16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Camilloni A, Nati G, Maggiolini P, Romanelli A, Latina R. Chronic non-cancer pain in primary care: an Italian cross-sectional study. Signa Vitae. 2021;7:54–62.

    Google Scholar 

  18. Dai R, Peng X, Lin B, Xu D, Lv R. NIR II luminescence imaging for sentinel lymph node and enhanced chemo-/photothermal therapy for breast cancer. Bioconjugate Chem. 2021;32:2117–27.

    Article  CAS  Google Scholar 

  19. Petsalaki E, Dandoulaki M, Zachos G. Chmp4c is required for stable kinetochore-microtubule attachments. Chromosoma. 2018;127:461–73.

    Article  CAS  PubMed  Google Scholar 

  20. Casares-Arias J, Gonzalez MU, San Paulo A, Ventimiglia LN, Sadler JBA, Miguez DG, et al. Midbody remnant inheritance is regulated by the ESCRT subunit CHMP4C. iScience. 2020;23:101244.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yang XX, Ma M, Sang MX, Zhang XY, Zou NY, Zhu SC. Knockdown of FAM83D enhances radiosensitivity in coordination with irradiation by inhibiting EMT via the Akt/GSK-3beta/Snail signaling pathway in human esophageal cancer cells. OncoTargets Ther. 2020;13:4665–78.

    Article  CAS  Google Scholar 

  22. Huang Y, Guo Y, Xu Y, Liu F, Dai S. Flotillin-1 promotes EMT of gastric cancer via stabilizing Snail. PeerJ. 2022;10:e13901.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Gao Y, Xiang D, Li W, Zheng X, Wang L, Li Z, et al. BRAF(V600E) mutation-responsive miRNA-222-3p promotes metastasis of papillary thyroid cancer cells via snail-induced EMT. Front Endocrinol. 2022;13:843334.

    Article  Google Scholar 

  24. Wang WD, Shang Y, Li Y, Chen SZ. Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation. Acta Pharm Sin. 2019;40:1219–27.

    Article  CAS  Google Scholar 

  25. Mezencev R, Matyunina LV, Jabbari N, McDonald JF. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity. BMC Cancer. 2016;16:236.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the Technology Research Projects of the Science Technology Department of Taizhou City (Grant No. 20ywa38).

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou, Zhejiang, 318000, China

    Xiaoyan Jin, Jian Wang, Zhengyi Wang, Wenyang Pang & Yong Chen

  2. Department of Anesthesiology, Taizhou Municipal Hospital, Taizhou, Zhejiang, 318000, China

    Li Yang

Authors
  1. Xiaoyan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhengyi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenyang Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation and experiments were performed by XJ. Data collection and analysis were performed by JW, ZW and WP. The first draft of the manuscript was written by CY and LY and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Li Yang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethics approval

Ethical approval was obtained from the Ethics Committee of Taizhou Municipal Hospital.

Informed consent

Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, X., Wang, J., Wang, Z. et al. Chromatin-modifying protein 4C (CHMP4C) affects breast cancer cell growth and doxorubicin resistance as a potential breast cancer therapeutic target. J Antibiot 77, 93–101 (2024). https://doi.org/10.1038/s41429-023-00683-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41429-023-00683-2

Search

Advanced search

Quick links